drugset

drugset / Trial / NCT06799611

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

NCT06799611 ↗

Phase 2 Recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of CM336 in the treatment of refractory adult primary immune thrombocytopenia

Timeline

Start: 2025-03-03
Primary completion: 2026-01-31
Completion: 2027-01-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM336	Monoclonal antibody	—	Subcutaneous

Indications